Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GeRX-261
- Development stage
- Preclinical
- Lead developer
- Gelteq
- Modality
- Hydrogel Systems → Drug Delivery Systems
- Administration
- Oral
01
Overview
GeRX-261 is an investigational oral gel formulation developed by Gelteq for the treatment of mental health disorders. Utilizing Gelteq's proprietary gel-based drug delivery platform, GeRX-261 is designed to improve the bioavailability, taste-masking, and patient compliance of its active pharmaceutical ingredient, particularly for patients who suffer from dysphagia or have difficulty swallowing conventional solid dosage forms. The candidate is currently in the early optimization and development stage.
Beyond the preview
Go deeper on GeRX-261.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GeRX-261.